We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
luis betancourt
Dec 08, 2020
Tucatinib,Capecitabine,Trastuzumab.
Volker Gressler
Dec 11, 2020
Trastuzuamb +Pertuzumab +Fulvestrant
Silvana Costa
Dec 11, 2020
Trastuzuamb + Pertuzumab + Fulvestrant
Oscar Rivero
Dec 11, 2020
Trastuzumab + pertuzumab + fulvestrant
Kimberly Langdon
Dec 11, 2020
Trastuzumab +pertuzumab + fulvestrant
souhila medrar
Dec 11, 2020
trastuzumab +pertuzumab+ fulvestrant
Bogdan Cristian Dinu
Dec 12, 2020
5 variant
EMADMOHSEN EL-NASHAR
Dec 13, 2020
According to the HER2CLIMB trial, Tucatinib,Capecitabine,Trastuzumab. as there was a statistically significant improvement in both progression-free and overall survival in the tucatinib arm.
nadim nagi
Dec 14, 2020
Tucatinib,Capcitabine,Trastuzumab as HER2CLIMB trial
Swapan Kumar Nath
Dec 28, 2020
Trastuzumab, Pertuzumab with fulvastrant is my choice
roberto romero
Feb 18, 2021
Trastuzumab, Pertuzumab with fulvastrant is my choice
Dec 23, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
luis betancourt
Dec 08, 2020
Volker Gressler
Dec 11, 2020
Silvana Costa
Dec 11, 2020
Oscar Rivero
Dec 11, 2020
Kimberly Langdon
Dec 11, 2020
souhila medrar
Dec 11, 2020
Bogdan Cristian Dinu
Dec 12, 2020
EMADMOHSEN EL-NASHAR
Dec 13, 2020
nadim nagi
Dec 14, 2020
Swapan Kumar Nath
Dec 28, 2020
roberto romero
Feb 18, 2021
Dec 23, 2024
Pending Moderator approval.